A programmed cell death ligand 1 (PDL1) and programmed death protein 1 (PD1) combine in a PD1/PDL1 pathway to control and maintain immune tolerance within the tumor microenvironment (TME) (Han et al., 2020). This evidence concerns the gene PDCD1 and neoplasm.